Open an account

GeoVax Labs

GOVX · NASDAQ

$0.2271−$0.0004 (−0.18%)TodayMarket closed ·
Prev close $0.2275

About GOVX

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 19 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. The company is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.

Employees
19
Headquarters
Smyrna, Georgia
Listed
Apr 4, 1994
Sector
Health Care
Industry
Biotechnology
Website
geovax.com

GOVX key statistics

Market cap
2.29M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
918.09K
Volume
190.83K
Open price
$0.23
High today
$0.24
Low today
$0.2204
52 Week high
$15.25
52 Week low
$0.226

GeoVax Labs (GOVX) at a glance

As of Oct 20, 2026, GeoVax Labs (GOVX) shares are priced at $0.2271, giving the company a market cap of 2.29M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.2204 and $0.24. The current price is 3.0% above the day's low and 5.4% below its high.

Volume so far is 190.83K shares, below the average of 918.09K shares a day.

Over the past year GeoVax Labs has ranged from $0.226 to $15.25, and now sits 0% of the way up that range.

GeoVax Labs met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.97 per share against an estimate of -$2.94.

The average analyst price target is $74.80, 32837.0% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 5 analystsAvg $74.80
Low
$10.10
Now
$0.2271
High
$210.00

GOVX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 49.8% on average.

  1. Q3 FY24: reported -$22.75 per share against an estimate of -$37.68
  2. Q4 FY24: reported -$7.50 per share against an estimate of -$19.58
  3. Q1 FY25: reported -$11.25 per share against an estimate of -$17.00
  4. Q2 FY25: reported -$8.75 per share against an estimate of -$9.18
  5. Q3 FY25: reported -$7.75 per share against an estimate of -$6.76
  6. Q4 FY25: reported -$0.005 per share against an estimate of -$6.29
  7. Q1 FY26: reported -$2.62 per share against an estimate of -$4.51
  8. Q2 FY26: reported -$0.97 per share against an estimate of -$2.94

GOVX news

  • World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

  • 'White House Adds Pandemic Response Staff as Ebola Cases Rise' - Bloomberg News

  • Akanksha Bakshi

    GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Avi Kapoor

    US Stocks Edge Lower; Advance Auto Parts Posts Upbeat Earnings

  • Avi Kapoor

    Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as GeoVax Labs

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.